Table 1.
Demographic and clinical characteristics in the drug-treated and untreated IgAN patients at the time of kidney biopsy and at the end of follow-up
| Clinical data | At the time of biopsy | At the end of follow-up | ||
|---|---|---|---|---|
| All cases | All cases | Drug-treated | Untreated | |
| N | 73 | 65 | 38 | 27 |
| Age (years) | 33.7 (16–76) | 33.9 (16–76) | 37.5 (16–76) | 28.8 (16–46)* |
| Duration of follow-up (months, range) | 48.9 (12–144) | 46.4 (12–144) | 52.8 (12–135) | |
| BMI (kg/m2) | 26.4 ± 5.2 | 27.1 ± 4.8 | 27.5 ± 5.4 | 25.2 ± 4.7* |
| Smokers (%) | 29 | 27.7 | 31.6 | 22.2 |
| Presenting clinical syndrome: | ||||
| Macroscopic hematuria (%) | 4 | 4.6 | 0 | 11.1 |
| Asymptomatic microhematuria (%) | 48 | 44.6 | 34.2 | 59.3 |
| Asymptomatic microhematuria and proteinuria (%) | 39 | 41.5 | 50.0 | 29.6 |
| NS (%) | 7 | 6.2 | 10.5 | 0 |
| Acute renal failure (%) | 1 | 1.5 | 2.6 | 0 |
| CKD (eGFR < 60 ml/min/1.73 m2) (%) | 1 | 1.5 | 2.6 | 0 |
| MAP (mmHg) | 94.5 ± 16.7 | 95.2 ± 9.1 | 96.2 ± 9.9 | 93.9 ± 7.7 |
| S-Creat (μmol/L) | 93.4 ± 70.7 | 94.4 ± 74.4 | 106.1 ± 94.4 | 77.2 ± 15.0* |
| eGFR (mean, ml/min per 1.73 m2) | 94.9 ± 30.7 | 85.8 ± 28.6 | 76.5 ± 29.1 | 98.8 ± 22.5** |
| eGFR >90 ml/min (N) | 38 | 34 | 16 | 18 |
| eGFR 60–89 ml/min (N) | 21 | 18 | 11 | 7 |
| eGFR >60 ml/min (N) | 13 | 13 | 11 | 2 |
| U-Prot (g/day, range) | 0.91 (0–10.2) | 0.79 (0–8.5) | 1.0 (0–8.5) | 0.5 (0–3.5)* |
| <1 (%) | 81 | 79 | 73.7 | 85.2 |
| 1–3.49 (%) | 11 | 15 | 13.2 | 14.8 |
| >3.5 (%) | 8 | 6 | 10.5 | 0 |
| Microhematuria (%) | 65.8 | 40.0 | 39.5 | 40.7 |
BMI body mass index, CKD chronic kidney disease, NS nephrotic syndrome, eGFR estimated glomerular filtration rate, MAP mean arterial pressure, U-Prot urinary protein excretion
Values are expressed as mean ± standard deviation or mean, or percent
* p-value < 0.05 versus Drug-treated; ** p-value < 0.01 versus Drug-treated